Cargando…

Healthcare Costs of Metastatic Cutaneous Melanoma in the Era of Immunotherapeutic and Targeted Drugs

Immunotherapeutic and targeted drugs improved survival of patients with metastatic melanoma. There is, however, a lack of evidence regarding their healthcare costs in clinical practice. The aim of our study was to provide insight into real-world healthcare costs of patients with metastatic cutaneous...

Descripción completa

Detalles Bibliográficos
Autores principales: Leeneman, Brenda, Uyl-de Groot, Carin A., Aarts, Maureen J. B., van Akkooi, Alexander C. J., van den Berkmortel, Franchette W. P. J., van den Eertwegh, Alfons J. M., de Groot, Jan Willem B., Herbschleb, Karin H., van der Hoeven, Jacobus J. M., Hospers, Geke A. P., Kapiteijn, Ellen, Piersma, Djura, van Rijn, Rozemarijn S., Suijkerbuijk, Karijn P. M., ten Tije, Albert J., van der Veldt, Astrid A. M., Vreugdenhil, Gerard, Wouters, Michel W. J. M., Haanen, John B. A. G., Franken, Margreet G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7225943/
https://www.ncbi.nlm.nih.gov/pubmed/32325748
http://dx.doi.org/10.3390/cancers12041003
_version_ 1783534171137769472
author Leeneman, Brenda
Uyl-de Groot, Carin A.
Aarts, Maureen J. B.
van Akkooi, Alexander C. J.
van den Berkmortel, Franchette W. P. J.
van den Eertwegh, Alfons J. M.
de Groot, Jan Willem B.
Herbschleb, Karin H.
van der Hoeven, Jacobus J. M.
Hospers, Geke A. P.
Kapiteijn, Ellen
Piersma, Djura
van Rijn, Rozemarijn S.
Suijkerbuijk, Karijn P. M.
ten Tije, Albert J.
van der Veldt, Astrid A. M.
Vreugdenhil, Gerard
Wouters, Michel W. J. M.
Haanen, John B. A. G.
Franken, Margreet G.
author_facet Leeneman, Brenda
Uyl-de Groot, Carin A.
Aarts, Maureen J. B.
van Akkooi, Alexander C. J.
van den Berkmortel, Franchette W. P. J.
van den Eertwegh, Alfons J. M.
de Groot, Jan Willem B.
Herbschleb, Karin H.
van der Hoeven, Jacobus J. M.
Hospers, Geke A. P.
Kapiteijn, Ellen
Piersma, Djura
van Rijn, Rozemarijn S.
Suijkerbuijk, Karijn P. M.
ten Tije, Albert J.
van der Veldt, Astrid A. M.
Vreugdenhil, Gerard
Wouters, Michel W. J. M.
Haanen, John B. A. G.
Franken, Margreet G.
author_sort Leeneman, Brenda
collection PubMed
description Immunotherapeutic and targeted drugs improved survival of patients with metastatic melanoma. There is, however, a lack of evidence regarding their healthcare costs in clinical practice. The aim of our study was to provide insight into real-world healthcare costs of patients with metastatic cutaneous melanoma. Data were obtained from the Dutch Melanoma Treatment Registry for patients who were registered between July 2012 and December 2018. Mean total/monthly costs per patient were reported for all patients, patients who did not receive systemic therapy, and patients who received systemic therapy. Furthermore, mean episode/monthly costs per line of therapy and drug were reported for patients who received systemic therapy. Mean total/monthly costs were € 89,240/€ 6809: € 7988/€ 2483 for patients who did not receive systemic therapy (n = 784) and € 105,078/€ 7652 for patients who received systemic therapy (n = 4022). Mean episode/monthly costs were the highest for nivolumab plus ipilimumab (€ 79,675/€ 16,976), ipilimumab monotherapy (€ 79,110/€ 17,252), and dabrafenib plus trametinib (€ 77,053/€ 12,015). Dacarbazine yielded the lowest mean episode/monthly costs (€ 6564/€ 2027). Our study showed that immunotherapeutic and targeted drugs had a large impact on real-world healthcare costs. As new drugs continue entering the treatment landscape for (metastatic) melanoma, it remains crucial to monitor whether the benefits of these drugs outweigh their costs.
format Online
Article
Text
id pubmed-7225943
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-72259432020-05-18 Healthcare Costs of Metastatic Cutaneous Melanoma in the Era of Immunotherapeutic and Targeted Drugs Leeneman, Brenda Uyl-de Groot, Carin A. Aarts, Maureen J. B. van Akkooi, Alexander C. J. van den Berkmortel, Franchette W. P. J. van den Eertwegh, Alfons J. M. de Groot, Jan Willem B. Herbschleb, Karin H. van der Hoeven, Jacobus J. M. Hospers, Geke A. P. Kapiteijn, Ellen Piersma, Djura van Rijn, Rozemarijn S. Suijkerbuijk, Karijn P. M. ten Tije, Albert J. van der Veldt, Astrid A. M. Vreugdenhil, Gerard Wouters, Michel W. J. M. Haanen, John B. A. G. Franken, Margreet G. Cancers (Basel) Article Immunotherapeutic and targeted drugs improved survival of patients with metastatic melanoma. There is, however, a lack of evidence regarding their healthcare costs in clinical practice. The aim of our study was to provide insight into real-world healthcare costs of patients with metastatic cutaneous melanoma. Data were obtained from the Dutch Melanoma Treatment Registry for patients who were registered between July 2012 and December 2018. Mean total/monthly costs per patient were reported for all patients, patients who did not receive systemic therapy, and patients who received systemic therapy. Furthermore, mean episode/monthly costs per line of therapy and drug were reported for patients who received systemic therapy. Mean total/monthly costs were € 89,240/€ 6809: € 7988/€ 2483 for patients who did not receive systemic therapy (n = 784) and € 105,078/€ 7652 for patients who received systemic therapy (n = 4022). Mean episode/monthly costs were the highest for nivolumab plus ipilimumab (€ 79,675/€ 16,976), ipilimumab monotherapy (€ 79,110/€ 17,252), and dabrafenib plus trametinib (€ 77,053/€ 12,015). Dacarbazine yielded the lowest mean episode/monthly costs (€ 6564/€ 2027). Our study showed that immunotherapeutic and targeted drugs had a large impact on real-world healthcare costs. As new drugs continue entering the treatment landscape for (metastatic) melanoma, it remains crucial to monitor whether the benefits of these drugs outweigh their costs. MDPI 2020-04-18 /pmc/articles/PMC7225943/ /pubmed/32325748 http://dx.doi.org/10.3390/cancers12041003 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Leeneman, Brenda
Uyl-de Groot, Carin A.
Aarts, Maureen J. B.
van Akkooi, Alexander C. J.
van den Berkmortel, Franchette W. P. J.
van den Eertwegh, Alfons J. M.
de Groot, Jan Willem B.
Herbschleb, Karin H.
van der Hoeven, Jacobus J. M.
Hospers, Geke A. P.
Kapiteijn, Ellen
Piersma, Djura
van Rijn, Rozemarijn S.
Suijkerbuijk, Karijn P. M.
ten Tije, Albert J.
van der Veldt, Astrid A. M.
Vreugdenhil, Gerard
Wouters, Michel W. J. M.
Haanen, John B. A. G.
Franken, Margreet G.
Healthcare Costs of Metastatic Cutaneous Melanoma in the Era of Immunotherapeutic and Targeted Drugs
title Healthcare Costs of Metastatic Cutaneous Melanoma in the Era of Immunotherapeutic and Targeted Drugs
title_full Healthcare Costs of Metastatic Cutaneous Melanoma in the Era of Immunotherapeutic and Targeted Drugs
title_fullStr Healthcare Costs of Metastatic Cutaneous Melanoma in the Era of Immunotherapeutic and Targeted Drugs
title_full_unstemmed Healthcare Costs of Metastatic Cutaneous Melanoma in the Era of Immunotherapeutic and Targeted Drugs
title_short Healthcare Costs of Metastatic Cutaneous Melanoma in the Era of Immunotherapeutic and Targeted Drugs
title_sort healthcare costs of metastatic cutaneous melanoma in the era of immunotherapeutic and targeted drugs
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7225943/
https://www.ncbi.nlm.nih.gov/pubmed/32325748
http://dx.doi.org/10.3390/cancers12041003
work_keys_str_mv AT leenemanbrenda healthcarecostsofmetastaticcutaneousmelanomaintheeraofimmunotherapeuticandtargeteddrugs
AT uyldegrootcarina healthcarecostsofmetastaticcutaneousmelanomaintheeraofimmunotherapeuticandtargeteddrugs
AT aartsmaureenjb healthcarecostsofmetastaticcutaneousmelanomaintheeraofimmunotherapeuticandtargeteddrugs
AT vanakkooialexandercj healthcarecostsofmetastaticcutaneousmelanomaintheeraofimmunotherapeuticandtargeteddrugs
AT vandenberkmortelfranchettewpj healthcarecostsofmetastaticcutaneousmelanomaintheeraofimmunotherapeuticandtargeteddrugs
AT vandeneertweghalfonsjm healthcarecostsofmetastaticcutaneousmelanomaintheeraofimmunotherapeuticandtargeteddrugs
AT degrootjanwillemb healthcarecostsofmetastaticcutaneousmelanomaintheeraofimmunotherapeuticandtargeteddrugs
AT herbschlebkarinh healthcarecostsofmetastaticcutaneousmelanomaintheeraofimmunotherapeuticandtargeteddrugs
AT vanderhoevenjacobusjm healthcarecostsofmetastaticcutaneousmelanomaintheeraofimmunotherapeuticandtargeteddrugs
AT hospersgekeap healthcarecostsofmetastaticcutaneousmelanomaintheeraofimmunotherapeuticandtargeteddrugs
AT kapiteijnellen healthcarecostsofmetastaticcutaneousmelanomaintheeraofimmunotherapeuticandtargeteddrugs
AT piersmadjura healthcarecostsofmetastaticcutaneousmelanomaintheeraofimmunotherapeuticandtargeteddrugs
AT vanrijnrozemarijns healthcarecostsofmetastaticcutaneousmelanomaintheeraofimmunotherapeuticandtargeteddrugs
AT suijkerbuijkkarijnpm healthcarecostsofmetastaticcutaneousmelanomaintheeraofimmunotherapeuticandtargeteddrugs
AT tentijealbertj healthcarecostsofmetastaticcutaneousmelanomaintheeraofimmunotherapeuticandtargeteddrugs
AT vanderveldtastridam healthcarecostsofmetastaticcutaneousmelanomaintheeraofimmunotherapeuticandtargeteddrugs
AT vreugdenhilgerard healthcarecostsofmetastaticcutaneousmelanomaintheeraofimmunotherapeuticandtargeteddrugs
AT woutersmichelwjm healthcarecostsofmetastaticcutaneousmelanomaintheeraofimmunotherapeuticandtargeteddrugs
AT haanenjohnbag healthcarecostsofmetastaticcutaneousmelanomaintheeraofimmunotherapeuticandtargeteddrugs
AT frankenmargreetg healthcarecostsofmetastaticcutaneousmelanomaintheeraofimmunotherapeuticandtargeteddrugs